|Day Low/High||155.10 / 159.90|
|52 Wk Low/High||105.05 / 178.45|
In this day and age, companies must be 'disruptors' or get left in the dust.
With more gains likely on the charts let's come up with a strategy to take advantage of this opportunity.
Jim Cramer explains why his Action Alerts Plus charitable portfolio is hanging on to Abbott Laboratories.
After a slump early last year, the smartwatch's sales have been rebounding. New features unveiled at Apple's WWDC conference could aid its momentum later this year.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said reports of Apple developing a diabetes testing product is not a reason to own the stock.
Old-line momentum favorites fare well.
These companies show signs of a change of direction.
The medical device company has been trading sideways for a long time and is likely to continue in the manner.
But several airline and retail stocks are proving highly volatile.
Results on conference picks are split as hedge fund industry contends with criticism.
David Einhorn, Jim Chanos presentations close out 2106's Sohn Investment Conference.
Shares of DexCom have bounced back 15% since hitting a 52-week low early last month, yet are still down 20% so far in 2016.
A combination of price and range compression often precedes volatility squeeze breakouts.
Dexcom's Ashley Benedict shares her experience from diagnosis at age 7 to becoming an educator at the company that improved the quality of her life.
Dexcom CEO Terry Gregg reviews the tremendous growth the company saw in 2013 and how the company is improving the quality of life for diabetics. TheStreet's Jill Malandrino reports from the Nasdaq MarketSite in New York.